Roueen Rafeyan, MD
Addiction Medicine · Chicago, ILNPI 1003891458
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,902,893 of the $2,357,299 with a category attached, or 80.7%. It is spread thinly across 29 manufacturers, the largest accounting for just 18.5%. Among addiction medicine clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 2,969 payments — averaging $793.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$436K
- Alkermes, Inc.$410K
- Otsuka America Pharmaceutical, Inc.$406K
- Neurocrine Biosciences, Inc.$357K
- Teva Pharmaceuticals USA, Inc.$275K
- Axsome Therapeutics, Inc.$87K
- plus $385K from 23 others
Across 1,176 payments — averaging $9932.85 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Teva Pharmaceuticals USA, Inc.$6M
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2.6M
- E.r. Squibb & Sons, L.L.C.$1.6M
- Sumitomo Pharma America, Inc.$559K
- Hoffmann-la Roche Limited$445K
- AbbVie$266K
- plus $218K from 9 others
What the payments were for
- Consulting fees$179,3658%
- Speaking & faculty fees$1,902,89381%
- Travel & lodging$203,4999%
- Food & beverage$69,7343%
- Education$3940%
- Gifts$1,4140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 520 | $436,275 |
| Alkermes, Inc. | 456 | $409,890 |
| Otsuka America Pharmaceutical, Inc. | 588 | $406,480 |
| Neurocrine Biosciences, Inc. | 313 | $357,003 |
| Teva Pharmaceuticals USA, Inc. | 277 | $275,385 |
| Axsome Therapeutics, Inc. | 90 | $87,279 |
| Sunovion Pharmaceuticals Inc. | 121 | $86,988 |
| E.r. Squibb & Sons, L.L.C. | 78 | $70,057 |
| AbbVie(2 entities) | 143 | $65,281 |
| Johnson & Johnson | 102 | $64,192 |
| H. Lundbeck A S | 12 | $55,441 |
| Vanda Pharmaceuticals Inc. | 31 | $17,304 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 22 | $15,671 |
| Takeda Pharmaceuticals U.S.A., Inc. | 43 | $5,568 |
| USWM, LLC | 14 | $1,758 |
| Lundbeck LLC | 108 | $1,702 |
| Bausch Health US, LLC | 18 | $345 |
| Indivior Inc. | 6 | $121 |
| Idorsia Pharmaceuticals US Inc | 6 | $111 |
| Neuronetics, Inc. | 1 | $107 |
| Noven Therapeutics, LLC | 5 | $81 |
| Supernus Pharmaceuticals, Inc. | 5 | $80 |
| Jazz Pharmaceuticals Inc. | 4 | $72 |
| Acadia Pharmaceuticals Inc | 1 | $28 |
| Shire North American Group Inc | 1 | $22 |
| Orexo US, Inc. | 1 | $21 |
| MDD US Operations, LLC | 1 | $20 |
| Noven Pharmaceuticals, Inc. | 1 | $14 |
| Corium, LLC | 1 | $4 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ARISTADA$905,184
- LYBALVI$701,641
- CAPLYTA$428,838
- REXULTI$383,866
- INGREZZA$352,438
- ARISTADA INITIO$212,201
- UZEDY$106,686
- AUSTEDO$91,331
- Auvelity$85,562
- LATUDA$85,509
- ABILIFY MAINTENA$79,684
- Austedo XR$68,911
- VRAYLAR$60,029
- INVEGA SUSTENNA$59,003
- INVEGA TRINZA$58,452
- COBENFY$58,243
- Fanapt$16,665
- ABILIFY ASIMTUFII$6,338
- TRINTELLIX$4,836
- SPRAVATO$3,423
How this compares
$2,357,299 in reported general payments places this provider in the 95th percentile of 47 addiction medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega TrinzaPaliperidone Palmitate | 12 | $124,804 |
| AplenzinBupropion Hbr | 12 | $71,309 |
| AristadaAripiprazole Lauroxil | 17 | $65,289 |
| RexultiBrexpiprazole | 20 | $29,769 |
| AuvelityDextromethorphan Hbr/Bupropion | 11 | $11,849 |
| Paliperidone ErPaliperidone | 15 | $2,999 |
| Quetiapine Fumarate | 26 | $1,113 |
| Haloperidol Decanoate | 16 | $805 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 23 | $779 |
| Divalproex Sodium ErDivalproex Sodium | 13 | $730 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 27 | $691 |
| Clonazepam | 57 | $408 |
| Olanzapine | 13 | $377 |
| Risperidone | 41 | $372 |
| Lurasidone Hcl | 13 | $301 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Trinza | $64,192 | $124,80412 claims |
| Bausch Health US, LLCAplenzin | $345 | $71,30912 claims |
| Alkermes, Inc.Aristada | $409,890 | $65,28917 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $406,480 | $29,76920 claims |
| Axsome Therapeutics, Inc.Auvelity | $87,279 | $11,84911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 47 addiction medicine providers in Illinois.
Other addiction medicine in Chicago
- Francesco TaniChicago$4K
- Kathleen McDonoughChicago$582
- Tiffany TahataChicago$416
- Ruchi FitzgeraldChicago$379
- Luciana RibeiroChicago$339
- Dora DixieChicago$237
- Jonathan TanawanChicago$160
- Samantha QuarlessChicago$131
- Michael BaldingerChicago$110
- Fazeelah IbrahimChicago$101
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.